BPH vs GSKH

BPHCBP p.l.c. ADRhedged

GSKHCGSK plc ADRhedged

In short

BPH Most single-stock ETFs chase leverage. This one does the opposite: it holds BP through an ADR and pairs it with a currency contract meant to strip out the pound-dollar swing, so you get the oil major's story without the FX one.

GSKH GSK, minus the currency noise. A single-stock ADR wrapper on the UK pharma giant with the pound hedge built in, so what you own is the stock's move rather than the exchange rate's.

Stated mandate

BPH The Series seeks to provide returns that generally correspond, before fees and expenses, to BP p.l.c.'s ordinary shares in the company's local market.

GSKH The fund is an ADR-hedged ETF providing exposure to GSK plc, a global pharmaceutical and biotechnology company focused on vaccines.

Why people hold it

• BPH The hedge is baked in. A currency contract sits alongside the BP ADR to reduce the foreign-exchange exposure that normally tags along with an overseas listing.precidian.com
• 0.19% a year, matching the median for its currency-hedged peer group and the same sticker as sibling ADRhedged funds like HSBH and SHEH.
• One US-listed ticker replaces the ADR-plus-forward setup a hedged investor would otherwise build by hand. Distributions come quarterly.

• GSKH The currency hedge is built into the wrapper, so holding a UK-listed drugmaker stays a pharma call instead of doubling as a pound call.precidian.com
• 0.19% a year, the same sticker carried across the ADRhedged lineup, for a hedge most individual investors cannot run cheaply themselves.
• One US-listed ticker covers the ADR and the hedge together, with distributions on a quarterly cadence.

Worth knowing

• BPH One company, one sector. BP drives every move here, and the hedge addresses currency, not oil prices or company-specific news.
• A small fund that trades thinly, so spreads and limit orders deserve more attention than with a heavily traded name.
• Launched in 2025, so the live record behind the hedge is still short.

• GSKH Small and thinly traded, which usually means wider bid-ask spreads and more of the cost showing up in the trade itself.
• One company, one story: GSK's pipeline, patents and litigation headlines drive the entire position, with no diversification to soften them.
• A hedge works in both directions, stripping out pound gains along with pound losses, and the fund only launched in 2025, so its record is short.

Full BPH profile⁠

Full GSKH profile⁠